Ipsen Regulated Information | Investor Relations
Skip to main content
Ipsen Home Page
Press shift tab to select search category
Loading...
  • Newsroom arrow down
      < Back
    • Newsroom
    • Press Releases
    • Media Updates
    • Media Resources
    • Media Contacts
    • Subscribe
  • Investors arrow down
      < Back
    • Investors
    • Investors
    • Financial Results
    • Annual Reports & Regulated Information
    • Investor Events & Financial Calendar
    • Shareholder Information
    • Subscribe
    • Ratings & Bonds
  • Careers arrow down
      < Back
    • Careers
    • Careers
    • Working at Ipsen
    • Culture
    • Job Search
  • Contacts arrow down
      < Back
    • Contacts
    • Contacts
    • Our Locations
    • Report Side Effects
    • Subscribe
  • Press shift tab to select search category
    Loading...
  • English  EN     Français  FR     EN  arrow_down
    • English EN
    • Français FR
  •  Global
    < Back
    • Global EN FR
    • Annual Report EN FR
    • Americas
    • Asia Pacific
    • Europe
    • Middle East & Africa
    • United States
    • Brazil
    • Canada
    • Mexico
    • Australia
    • China
    • Singapore
    • South Korea
    • Japan
    • Belgium
    • Ukraine
    • UK
    • Germany
    • France
    • Nordics
    • Greece
    • Italy
    • Netherlands
    • Spain
    • Poland
    • Russia
    • Czech Republic
    • Switzerland
    • Austria
    • UAE & Gulf
    • Saudi Arabia
  • Home
  • Company
      < Back
    • Company
    • Company
    • Leadership
    • History
    • Fondation Ipsen
  • Expertise
      < Back
    • Expertise
    • Oncology
    • Rare Disease
    • Neuroscience
    • Medicines
  • Science
      < Back
    • Science
    • Science
        < Back
      • Science
      • Oncology
      • Rare Disease
      • Neuroscience
    • Profiles
    • Partnering
        < Back
      • Partnering
      • Therapeutic focus
      • Meet the team
    • Clinical Trials
        < Back
      • Clinical Trials
      • Lay Summaries
      • Find Clinical Trials
    • Pipeline
  • Sustainability
      < Back
    • Sustainability
    • Sustainability
    • Environment
    • Patients
    • People
    • Governance
    • Our Standards
  • Patients
      < Back
    • Patients
    • Patients
    • Together for Oncology
    • Together for Rare Disease
    • Together for Neuroscience
    • Collaborate with us
  • Stories
  1. Home
  2. Investors
  3. Regulated Information

Regulated Information

  • Regulated Information
  • Shareholders Meeting

Period

recent search

Reset

Showing: 1 – 05 of 166 Regulated Information

27 July 2023

27 July 2023

Download Ipsen S.A. publishes its 2023 Half-Year Financial Report
Ipsen S.A. publishes its 2023 Half-Year Financial Report

25 July 2023

25 July 2023

Download IPSEN - Buy-back programme - Art 5 of MAR - Week 29 - 2023
IPSEN – Buy-back programme – Art 5 of MAR – Week 29 – 2023

24 July 2023

24 July 2023

Download Ipsen announces a simplification of the concert of its principal shareholders representing 56.62% of the share capital and 72.36% of voting rights - effective from December 19, 2023
Ipsen announces a simplification of the concert of its principal shareholders representing 56.62% of the share capital and 72.36% of voting rights – effective from December 19, 2023

18 July 2023

18 July 2023

Download IPSEN - Buy-back programme - Art 5 of MAR - Week 28 - 2023
IPSEN – Buy-back programme – Art 5 of MAR – Week 28 – 2023

11 July 2023

11 July 2023

Download IPSEN - Buy-back programme - Art 5 of MAR - Week 27 - 2023
IPSEN – Buy-back programme – Art 5 of MAR – Week 27 – 2023

1 … 20 21 22 23 24 25 26 … 34

IPN price

€163.90

 €0.00 (0.00%)

  • Media Resources
  • Annual Report
  • Contacts
  • Our Locations
Ipsen logo
LinkedIn Instagram Facebook Youtube
  • Terms and Conditions
  • Cookie Policy
  • Global Privacy Policy

© Ipsen Pharma. All rights reserved - 2026

You are now leaving the Ipsen group global website. To continue, please click on Continue?

Continue